TIDMHVO
hVIVO plc
27 September 2019
hVIVO plc
("hVIVO" or the "Company")
hVIVO to present at the upcoming 2019 European Respiratory
Society (ERS) International Congress in Madrid, Spain
London, UK - 27 September 2019: hVIVO plc (AIM: HVO), an
industry leading clinical development services business supporting
product development for companies developing antivirals, vaccines
and respiratory therapeutics today announced it will be presenting
at the European Respiratory Society Congress being held on
September 28 - October 2, 2019 at the IFEMA, Feria de Madrid,
Madrid, Spain.
The first presentation will evaluate the use of lower
respiratory symptoms as a key endpoint to be used in trials along
with the relationships between the endpoint and clinical markers
such as lung function and asthma control. The second presentation
will focus on the patterns of the immune response to a viral
exacerbation in asthmatics and the timing profile of white blood
cells as well as nasal and blood immune biomarkers. These
presentations highlight the utility of the hVIVO viral challenge
model as well as help inform trial design and endpoint
selection.
Andrew Catchpole, Director, Clinical Science, commented; "We are
delighted that our abstracts have been accepted for presentation at
the prestigious ERS International Congress. The data summarised in
the posters is encouraging and supports our belief that the
challenge model is not only helpful as a proof-of-concept for the
effectiveness of agents directed at the viruses, but also as
proof-of-mechanism for novel products in diseases where respiratory
viruses are known to induce exacerbations."
Poster discussion presentation details:
Title: A key endpoint in viral challenge models of asthma
exacerbations Poster
Authors: Michael. A. Ghebre, Alan S. Bell, Alex J. Mann
Date & Time: 29.09.2019 at 08:30 CEST
Session Category: Airway Physiology 08:30-10:30
Presenter: Alan S. Bell, Director of Translational
Operations
Location: 6D
Conference Reference Number: 347
Oral presentation details:
Title: Temporal relationships of cytokines, chemokines and
cellular biomarkers during Human Rhinovirus (HRV) infection in
asthmatics
Authors: Alex J Mann, Michael A Ghebre, Alan S Bell
Date & Time: 01.10.2019 at 10:15 CEST
Session Category: Blood Eosinophils and More in Airway Diseases
08:30-10:30
Presenter: Alan S. Bell, Director of Translational
Operations
Location: 8A
Conference Reference Number: 3564
A copy of the presentation materials will be made available
here: https://hvivo.com/news-media/scientific-papers/
For further information please contact:
hVIVO plc
Fleur Wood (EVP, Investor Relations & Communications) +44 207 756 1300
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO is an industry leading clinical development services
business supporting product development for customers developing
antivirals, vaccines and respiratory therapeutics. Leveraging human
disease models in human rhinovirus (HRV), RSV, Influenza (Flu)
Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO
platform illuminates the entire disease cycle in people from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted 56 clinical studies and inoculated over 2900
volunteers.
Forward-looking statements
This announcement includes statements that are, or may be deemed
to be, forward-looking statements. These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms anticipates, believes, estimates, expects,
intends, may, plans, projects, should or will, or, in each case,
their negative or other variations or comparable terminology, or by
discussions of strategy, plans, objectives, goals, future events or
intentions. These forward-looking statements include all matters
that are not historical facts. Any forward-looking statements in
this announcement reflect the Group's (or, as the case may be, the
hVIVO directors') current view with respect to future events and
are subject to risks relating to future events and other risks,
uncertainties and assumptions relating to the Group's operations,
results of operations and growth strategy. Investors should
specifically consider the factors identified in this announcement
which could cause actual results to differ before making an
investment decision.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABRGDCDSDBGCL
(END) Dow Jones Newswires
September 27, 2019 02:01 ET (06:01 GMT)
Retroscreen (LSE:RVG)
Historical Stock Chart
From Apr 2024 to May 2024
Retroscreen (LSE:RVG)
Historical Stock Chart
From May 2023 to May 2024